vs
ANI PHARMACEUTICALS INC（ANIP）とRapid7, Inc.（RPD）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $217.4M、Rapid7, Inc.の約1.1倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 1.4%、差は9.7%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 0.5%）。Rapid7, Inc.の直近四半期フリーキャッシュフローが多い（$36.4M vs $29.1M）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 3.0%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
Rapid7社は世界的に有名なサイバーセキュリティ企業で、脆弱性管理、脅威検知・対応、クラウドセキュリティ、セキュリティ分析などの総合的なソリューションを提供しています。テクノロジー、医療、金融、製造業などの各業種の企業や公共部門を顧客とし、サイバー脅威への効率的な対応を支援します。
ANIP vs RPD — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $217.4M |
| 純利益 | $27.5M | $3.1M |
| 粗利率 | — | 68.9% |
| 営業利益率 | 14.1% | 1.0% |
| 純利益率 | 11.1% | 1.4% |
| 売上前年比 | 29.6% | 0.5% |
| 純利益前年比 | 367.5% | 44.1% |
| EPS（希薄化後） | $1.14 | $0.05 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $217.4M | ||
| Q3 25 | $227.8M | $218.0M | ||
| Q2 25 | $211.4M | $214.2M | ||
| Q1 25 | $197.1M | $210.3M | ||
| Q4 24 | $190.6M | $216.3M | ||
| Q3 24 | $148.3M | $214.7M | ||
| Q2 24 | $138.0M | $208.0M | ||
| Q1 24 | $137.4M | $205.1M |
| Q4 25 | $27.5M | $3.1M | ||
| Q3 25 | $26.6M | $9.8M | ||
| Q2 25 | $8.5M | $8.3M | ||
| Q1 25 | $15.7M | $2.1M | ||
| Q4 24 | $-10.3M | $2.2M | ||
| Q3 24 | $-24.2M | $15.4M | ||
| Q2 24 | $-2.3M | $6.5M | ||
| Q1 24 | $18.2M | $1.4M |
| Q4 25 | — | 68.9% | ||
| Q3 25 | — | 70.2% | ||
| Q2 25 | — | 70.6% | ||
| Q1 25 | — | 71.7% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 70.7% | ||
| Q1 24 | — | 70.3% |
| Q4 25 | 14.1% | 1.0% | ||
| Q3 25 | 15.9% | 2.7% | ||
| Q2 25 | 6.6% | 1.6% | ||
| Q1 25 | 13.3% | -0.0% | ||
| Q4 24 | -2.3% | 3.4% | ||
| Q3 24 | -13.8% | 6.0% | ||
| Q2 24 | 3.7% | 2.5% | ||
| Q1 24 | 14.8% | 4.7% |
| Q4 25 | 11.1% | 1.4% | ||
| Q3 25 | 11.7% | 4.5% | ||
| Q2 25 | 4.0% | 3.9% | ||
| Q1 25 | 8.0% | 1.0% | ||
| Q4 24 | -5.4% | 1.0% | ||
| Q3 24 | -16.3% | 7.2% | ||
| Q2 24 | -1.7% | 3.1% | ||
| Q1 24 | 13.2% | 0.7% |
| Q4 25 | $1.14 | $0.05 | ||
| Q3 25 | $1.13 | $0.15 | ||
| Q2 25 | $0.36 | $0.13 | ||
| Q1 25 | $0.69 | $0.03 | ||
| Q4 24 | $-0.45 | $0.08 | ||
| Q3 24 | $-1.27 | $0.21 | ||
| Q2 24 | $-0.14 | $0.09 | ||
| Q1 24 | $0.82 | $0.02 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $474.7M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $540.7M | $154.7M |
| 総資産 | $1.4B | $1.7B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $474.7M | ||
| Q3 25 | $262.6M | $407.1M | ||
| Q2 25 | $217.8M | $511.7M | ||
| Q1 25 | $149.8M | $493.5M | ||
| Q4 24 | $144.9M | $521.7M | ||
| Q3 24 | $145.0M | $443.7M | ||
| Q2 24 | $240.1M | $442.6M | ||
| Q1 24 | $228.6M | $411.7M |
| Q4 25 | $540.7M | $154.7M | ||
| Q3 25 | $505.8M | $127.2M | ||
| Q2 25 | $436.8M | $90.4M | ||
| Q1 25 | $418.6M | $52.7M | ||
| Q4 24 | $403.7M | $17.7M | ||
| Q3 24 | $405.9M | $-5.1M | ||
| Q2 24 | $455.8M | $-52.6M | ||
| Q1 24 | $452.0M | $-86.4M |
| Q4 25 | $1.4B | $1.7B | ||
| Q3 25 | $1.4B | $1.7B | ||
| Q2 25 | $1.3B | $1.6B | ||
| Q1 25 | $1.3B | $1.6B | ||
| Q4 24 | $1.3B | $1.7B | ||
| Q3 24 | $1.3B | $1.6B | ||
| Q2 24 | $920.8M | $1.5B | ||
| Q1 24 | $914.5M | $1.5B |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $37.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $36.4M |
| FCFマージンFCF / 売上 | 11.8% | 16.8% |
| 設備投資強度設備投資 / 売上 | 0.5% | 0.5% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 12.01× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $146.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $37.6M | ||
| Q3 25 | $44.1M | $39.0M | ||
| Q2 25 | $75.8M | $47.5M | ||
| Q1 25 | $35.0M | $29.8M | ||
| Q4 24 | $15.9M | $63.8M | ||
| Q3 24 | $12.5M | $44.0M | ||
| Q2 24 | $17.4M | $32.9M | ||
| Q1 24 | $18.3M | $31.1M |
| Q4 25 | $29.1M | $36.4M | ||
| Q3 25 | $38.0M | $34.8M | ||
| Q2 25 | $71.8M | $46.6M | ||
| Q1 25 | $32.5M | $28.4M | ||
| Q4 24 | $13.5M | $62.6M | ||
| Q3 24 | $7.7M | $42.6M | ||
| Q2 24 | $13.0M | $32.6M | ||
| Q1 24 | $13.7M | $30.4M |
| Q4 25 | 11.8% | 16.8% | ||
| Q3 25 | 16.7% | 16.0% | ||
| Q2 25 | 34.0% | 21.8% | ||
| Q1 25 | 16.5% | 13.5% | ||
| Q4 24 | 7.1% | 28.9% | ||
| Q3 24 | 5.2% | 19.9% | ||
| Q2 24 | 9.4% | 15.7% | ||
| Q1 24 | 10.0% | 14.8% |
| Q4 25 | 0.5% | 0.5% | ||
| Q3 25 | 2.7% | 1.9% | ||
| Q2 25 | 1.9% | 0.4% | ||
| Q1 25 | 1.3% | 0.6% | ||
| Q4 24 | 1.3% | 0.5% | ||
| Q3 24 | 3.2% | 0.6% | ||
| Q2 24 | 3.2% | 0.1% | ||
| Q1 24 | 3.3% | 0.3% |
| Q4 25 | 1.10× | 12.01× | ||
| Q3 25 | 1.66× | 3.97× | ||
| Q2 25 | 8.87× | 5.70× | ||
| Q1 25 | 2.23× | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | 1.00× | 22.10× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
